US equities |
SPCX $175.16 ▲+2.38% NVDA $242.21 ▲+1.39% MU $1,068.40 ▲+0.42% MRVL $290.50 ▲+7.10% AMD $653.81 ▲+3.49% SNDK $1,678.27 ▼-1.52% AVGO $377.06 ▲+4.02% TSLA $380.69 ▲+0.52%
FinancialContent

Latest News about CSE:BHSC

Recent news which mentions CSE:BHSC

BioHarvest Sciences Hits Major Sales Milestone with VINIA seeing sales records
Tags CSE:BHSC OTC:CNVCF
From News Direct
BioHarvest Sciences Reports Robust Q1 2024 Financial Growth and Strategic Expansion Plans
Tags OTC:CNVCF CSE:BHSC
From News Direct
BioHarvest Sciences Reports Strong Financial Performance for 2023, Eyes Nasdaq Listing
Tags OTC:CNVCF CSE:BHSC
From News Direct
BioHarvest Sciences secures new state of the art 80,0000 square foot manufacturing facility
Tags OTC:CNVCF CSE:BHSC
From News Direct
BioHarvest Sciences adds key hires as company looks to ramp up CDMO Services Business Unit
Tags CSE:BHSC OTC:CNVCF
From News Direct
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
Tickers BHSC CCC ELTX ICR
Tags David Song Dr/ Freda Lewis/Hall of Conduit Pharmaceuticals Top Stories
From Benzinga
BioHarvest Sciences reports 113% year over year increase in revenue on strong sales of VINIA
Tags CSE:BHSC
From News Direct
BioHarvest Sciences closes first tranche of financing bringing in C$11.78M to Treasury
Tags CSE:BHSC
From News Direct
BioHarvest Sciences announces Health Canada has approved VINIA Sales in Canada
Tags CSE:BHSC
From News Direct
BioHarvest Sciences latest financial numbers shows continued growth for flagship product VINIA
Tags CSE:BHSC
From News Direct
BioHarvest Sciences 1Q financials show continued growth with a 209% year-over-year increase
Tags CSE:BHSC
From News Direct
BioHarvest Sciences announces launch of “Real Stories” media campaign for VINIA red grape supplement
Tags CSE:BHSC
From News Direct
BioHarvest Sciences to begin human clinical study with multiple sclerosis-related optic neuritis
Tags CSE:BHSC
From News Direct